In a filing, Bicara Therapeutics Inc revealed its Chief Legal Officer Meisner Lara unloaded Company’s shares for reported $0.17 million on Jun 16 ’25. In the deal valued at $10.43 per share,15,829 shares were sold. As a result of this transaction, Meisner Lara now holds 0 shares worth roughly $0.0.
Then, LARA S. MEISNER bought 31,658 shares, generating $343,173 in total proceeds.
Before that, Meisner Lara sold 79,146 shares. Bicara Therapeutics Inc shares valued at $1,021,211 were divested by the Chief Legal Officer at a price of $12.90 per share. As a result of the transaction, Meisner Lara now holds 0 shares, worth roughly $0.0.
Wells Fargo upgraded its Bicara Therapeutics Inc [BCAX] rating to an Equal weight from a an Underweight in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in mid April with a ‘”an Underweight”‘ rating. Wedbush began covering BCAX with “an Outperform” recommendation on February 06, 2025. H.C. Wainwright started covering the stock on December 06, 2024. It rated BCAX as “a Buy”.
Price Performance Review of BCAX
On Tuesday, Bicara Therapeutics Inc [NASDAQ:BCAX] saw its stock jump 0.49% to $10.23. Over the last five days, the stock has gained 10.48%. Nevertheless, the stocks have fallen -41.27% over the past one year.
Levels Of Support And Resistance For BCAX Stock
The 24-hour chart illustrates a support level at 9.97, which if violated will result in even more drops to 9.71. On the upside, there is a resistance level at 10.55. A further resistance level may holdings at 10.87.
How much short interest is there in Bicara Therapeutics Inc?
A steep rise in short interest was recorded in Bicara Therapeutics Inc stocks on 2025-06-13, dropping by -2.33 million shares to a total of 5.08 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 7.42 million shares. There was a decline of -45.87%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 05, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $48 price target.
